Recent studies have indicated that anti‐PD‐1 antibody therapy were effective for patients with refractory and relapsed Hodgkin's lymphoma, advanced multiple myeloma, and melanoma 12, 13, 14. Here, PDCD1 is linked to plasma cell myeloma.